Jacob Chacko - 15 Dec 2025 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Reporting relationship: PRESIDENT AND CEO, Director
Issuer ticker: ORIC
Reported as of: 15 Dec 2025
Net transaction value: -$302,368
SEC form: 4
Accepted by SEC: 17 Dec 2025, 19:18:55 UTC
Prior SEC filing: 08 Oct 2025
Next SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Christian Kuhlen, attorney-in-fact

Key filing fact

Jacob Chacko filed Form 4 for Oric Pharmaceuticals, Inc. (ORIC) on 17 Dec 2025.

Key facts

This page summarizes Jacob Chacko's Form 4 filing for Oric Pharmaceuticals, Inc. (ORIC).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 17 Dec 2025, 19:18.

Change

Previous filing in this sequence was filed on 08 Oct 2025.
Current net transaction value: -$302,368.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001608936 Primary reporting owner

Chacko Jacob

Relationship: PRESIDENT AND CEO, Director
Address: C/O ORIC PHARMACEUTICALS, INC., 240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO
Signature: /s/ Christian Kuhlen, attorney-in-fact
Signature date: 17 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORIC transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +83,666
Change %: +16%
Price: $0.000000
Shares after: 615,085
Date: 15 Dec 2025
Ownership: Direct
Footnotes: F1

ORIC transaction

Common Stock

Sale

Transaction value: $302,368
Shares: -33,374
Change %: -5.4%
Price: $9.06
Shares after: 581,711
Date: 16 Dec 2025
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ORIC transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -22,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 15 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,000
Exercise price
Footnotes: F1, F4

ORIC transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -28,333
Change %: -50%
Price: $0.000000
Shares after: 28,334
Date: 15 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 28,333
Exercise price
Footnotes: F1, F5

ORIC transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -33,333
Change %: -33%
Price: $0.000000
Shares after: 66,667
Date: 15 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 33,333
Exercise price
Footnotes: F1, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

Footnote F2

Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.

Footnote F3

Represents the weighted average share price of an aggregate total of 33,374 shares sold in the price range of $9.0257 to $9.095 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F4

1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.

Footnote F5

1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.

Footnote F6

1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.